Table III.
Population Pharmacodynamic Parameters
| Parameter (units) | Definition | Estimate | IIV | IOV |
|---|---|---|---|---|
| (Bootstrap 95% CI) | ||||
| Structural | ||||
| T in (min) | Duration of 0-order input of glucose into intestine | 85.9 | 39.7 | – |
| k out (min−1) | Rate constant for glucose utilization | 0.0146 (0.00987, 0.0271) | 83.1 (50.2, 122) | – |
| V Gc (L) | Central volume of distribution of glucose | 9.33a | – | – |
| V Gp (L) | Peripheral volume of distribution of glucose | 8.56a | – | – |
| Q G (L/min) | Intercompartmental clearance of glucose | 0.442a | – | – |
| k a (min−1) | Rate constant for glucose input into plasma | 0.0282 (0.0167, 0.0371) | – | – |
| F | Oral bioavailability of 50 g of glucose | 0.843 (0.518, 1.24) | 48.5 (0.478, 132) | |
| I max | Maximum inhibitory effect of pramlintide on k in | 0.995 (0.429, 1.0) | – | – |
| S max | Maximum stimulatory effect of pramlintide on T in | 1.26 (0.725, 2.98) | – | – |
| IC50 (pmol/L) | Pramlintide concentration at one-half I max | 23.8 (1.53, 162) | – | – |
| G 0 (mg/dL) | Baseline plasma glucose concentration | 161 (135, 190) | 38.4 (21.5, 52.7) | 37.1 (30.3, 42.8) |
| Residual variability | ||||
| Residual error | 15.7 (13.1, 18.1) | 39.5 (11.3, 61.5) | ||
IIV interindividual variability, expressed as standard deviation in percent; IOV interoccasion variability, expressed as standard deviation in percent
aObtained from reference (20)